Jan 10, 2024 05:12 PM
BUSINESS
Eisai Wins Chinese Approval for Its Alzheimer’s Drug Leqembi
00:00/00:00
Listen to this article
1x
Subscribe now
Listen to the full version
Listen to the full version
More than 55 million people suffer from Alzheimer’s disease worldwide, including 10 million in China. Photo: Bloomberg
(Bloomberg) — Eisai Co. Ltd.’s breakthrough therapy for Alzheimer’s disease has been cleared by regulators in China, giving the drugmaker a chance to tap growing demand for medicines to treat the debilitating condition in a rapidly aging population.
Eisai and partner Biogen Inc. are preparing to start sales as soon as July, the companies said in a statement Tuesday.
You've accessed an article available only to subscribers
VIEW OPTIONS
Share this article
Open WeChat and scan the QR code
Sign in with Google
Sign in with Facebook
Sign in with 财新